StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a research note released on Friday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reduced their price objective on shares of Trevena from $225.00 to $125.00 and set a buy rating on the stock in a research report on Thursday, May 16th.
Check Out Our Latest Stock Report on Trevena
Trevena Trading Down 11.2 %
Trevena (NASDAQ:TRVN – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($9.25) by $9.02. The business had revenue of $0.33 million during the quarter. Research analysts forecast that Trevena will post -32.25 earnings per share for the current fiscal year.
Institutional Trading of Trevena
A hedge fund recently bought a new stake in Trevena stock. Armistice Capital LLC acquired a new position in Trevena, Inc. (NASDAQ:TRVN – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned approximately 4.61% of Trevena at the end of the most recent quarter. Hedge funds and other institutional investors own 13.56% of the company’s stock.
About Trevena
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
See Also
- Five stocks we like better than Trevena
- The Significance of Brokerage Rankings in Stock Selection
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- What is the Hang Seng index?
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- What is a Stock Market Index and How Do You Use Them?
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.